DNLI241220C35000
- 1.06
- 0.000.00%
Denali Therapeutics Newsroom
B.Riley Financial Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $38
Denali Therapeutics Advances Brain Disease Therapies
We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely
Denali Therapeutics Insider Sold Shares Worth $1,932,665, According to a Recent SEC Filing
BofA Securities Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $34
B.Riley Financial Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $33
Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging
Denali Therapeutics (DNLI) Receives a Hold From Stifel Nicolaus
Morgan Stanley Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $41
Express News | Denali Therapeutics Inc : Wedbush Raises Target Price to $33 From $30
HC Wainwright & Co. Reiterates Buy on Denali Therapeutics, Maintains $90 Price Target
H.C. Wainwright Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $90
TD Cowen Maintains Denali Therapeutics(DNLI.US) With Buy Rating
Promising Developments and Strategic Advancements Propel Denali Therapeutics' Buy Rating
Denali Therapeutics Sees Fy24 Opex Increase of 5%-10% Year-over-year
Denali Therapeutics | 10-Q: Q3 2024 Earnings Report
Denali Therapeutics | 8-K: Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
Denali Therapeutics 3Q Loss/Shr 63c >DNLI
Express News | Denali Therapeutics Q3 Operating Expenses USD 123.187 Million